Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: Analysis by population and physiological approaches

被引:39
作者
Cox, DS [1 ]
Scott, KR [1 ]
Gao, HL [1 ]
Eddington, ND [1 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Pharmacokinet Biopharmaceut Lab, Baltimore, MD 21201 USA
关键词
D O I
10.1124/jpet.102.035436
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multidrug resistance (MDR), mediated by P-glycoprotein (Pgp) has been identified as altering the disposition of structurally diverse compounds. Previous in vitro studies in bovine brain microvascular endothelial cells and MCF/Adr [Adriamycin (doxorubicin)-resistant human breast cancer] cells displayed that the transport of enaminone anticonvulsants was influenced by Pgp. Therefore the objectives of this study was to further evaluate the influence of Pgp on the pharmacokinetics and tissue distribution of the enaminone analogs. mdr1ab (+/+) and mdr1ab (-/-) male mice (20 +/- 5 g) were administered DM5 (methyl 4-[(4'-chlorophenyl) amino]-6-methyl-2-oxo-3-cyclohexene-1-carboxylate) or DM44 (12.5 mg/kg, i.v.). Cohorts (n = 3) were sacrificed over a 12-h period, and samples were analyzed by a validated UV-high performance liquid chromatography assay method. Population analysis was used to estimate pharmacokinetic parameters and partition coefficients were determined for tissues. The clearance (0.51 versus 0.33 l/h/kg) and V-d (1.25 versus 0.93 l/ kg) of DM5 were found to be higher (p < 0.05), however the area under the curve (26.1 versus 38.2 μg/ ml . h) was lower (p < 0.05) in mdr1a/1b (-/-) versus mdr1a/1b (+/+) mice, respectively. Similar findings were observed for DM44. Tissues known to express Pgp such as the heart, liver, lung, and brain displayed 2-fold or higher tissue levels in mdr1a/1b (-/-) versus mdr1a/1b (+/+) mice. These results strongly suggest that Pgp may influence enaminone tissue distribution and pharmacokinetics and may play a significant role in the effective treatment of epilepsy with these analogs.
引用
收藏
页码:1096 / 1104
页数:9
相关论文
共 29 条
  • [21] SYNTHESIS AND ANTICONVULSANT ACTIVITY OF ENAMINONES .2. FURTHER STRUCTURE-ACTIVITY CORRELATIONS
    SCOTT, KR
    EDAFIOGHO, IO
    RICHARDSON, EL
    FARRAR, VA
    MOORE, JA
    TIETZ, EI
    HINKO, CN
    CHANG, HJ
    ELASSADI, A
    NICHOLSON, JM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (14) : 1947 - 1955
  • [22] Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy
    Sisodiya, SM
    Lin, WR
    Harding, BN
    Squier, MV
    Thom, M
    [J]. BRAIN, 2002, 125 : 22 - 31
  • [23] Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
    Sparreboom, A
    vanAsperen, J
    Mayer, U
    Schinkel, AH
    Smit, JW
    Meijer, DKF
    Borst, P
    Nooijen, WJ
    Beijnen, JH
    vanTellingen, O
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) : 2031 - 2035
  • [24] CELLULAR-LOCALIZATION OF THE MULTIDRUG-RESISTANCE GENE-PRODUCT P-GLYCOPROTEIN IN NORMAL HUMAN-TISSUES
    THIEBAUT, F
    TSURUO, T
    HAMADA, H
    GOTTESMAN, MM
    PASTAN, I
    WILLINGHAM, MC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) : 7735 - 7738
  • [25] MDR1 GENE-EXPRESSION IN BRAIN OF PATIENTS WITH MEDICALLY INTRACTABLE EPILEPSY
    TISHLER, DM
    WEINBERG, KI
    HINTON, DR
    BARBARO, N
    ANNETT, GM
    RAFFEL, C
    [J]. EPILEPSIA, 1995, 36 (01) : 1 - 6
  • [26] Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
    van Asperen, J
    van Tellingen, O
    Tijssen, F
    Schinkel, AH
    Beijnen, JH
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (01) : 108 - 113
  • [27] van Asperen J, 1999, J PHARMACOL EXP THER, V289, P329
  • [28] Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice
    vanAsperen, J
    Schinkel, AH
    Beijnen, JH
    Nooijen, WJ
    Borst, P
    vanTellingen, O
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (14) : 994 - 999
  • [29] VANASPEREN J, 1999, J PHARMACOL EXP THER, V28, P264